Evaluation of a novel serum biosignature for detecting TB in HIV-infected individuals

Location

Baltimore, Maryland

Dates

06/30/2017 - 06/29/2018

PI

Petros Karakousis, MD

This study will use multiple high-throughput modalities, including LC-MS/MS and RNA-seq, to detect a panel of host metabolites and miRNAs associated with active TB in HIV-infected individuals. Clinical samples are available through the Regional Prospective Observational Research in Tuberculosis (RePORT) International Consortium.

Projects

A randomized trial of preventive therapy for...

We are evaluating the efficacy and cost-effectiveness of levofloxacin preventive therapy for pediatric contacts of MDR TB...

Read More

ACTG trial A5343

Phase 2 safety study of bedaquiline and delamanid for the treatment of MDR-TB in South Africa

Read More

Evaluation of a novel serum biosignature for...

This study will use multiple high-throughput modalities, including LC-MS/MS and RNA-seq, to detect a panel of host metabolites...

Read More

Modeling the impact of spatially targeted TB...

 We have developed transmission models to understand the impact of TB vaccination strategies that target hotspots of...

Read More

APT: Assessing PA-824 for Tuberculosis

A Phase 2 clinical trial of PA-824, an investigational nitroimidazole, as part of multidrug therapy for pulmonary TB; in...

Read More